Shares of ChemoCentryx Inc. (NASDAQ:CCXI) were up 3.7% on Thursday . The company traded as high as $4.83 and last traded at $4.77, with a volume of 155,429 shares traded. The stock had previously closed at $4.60.

A number of analysts have recently weighed in on CCXI shares. Cowen and Company reaffirmed a “hold” rating on shares of ChemoCentryx in a research report on Thursday, May 19th. JPMorgan Chase & Co. reaffirmed a “buy” rating and set a $11.00 price objective on shares of ChemoCentryx in a research report on Tuesday, August 9th. Finally, Zacks Investment Research lowered ChemoCentryx from a “buy” rating to a “hold” rating in a research report on Monday, May 16th.

The firm’s market cap is $224.96 million. The company’s 50-day moving average is $4.56 and its 200-day moving average is $3.79.

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.